Latest Rhinitis Stories
Meda, a specialty pharma company, has announced that its new drug application for a newly formulated higher strength azelastine nasal spray has now been accepted by the FDA as complete for substantive review after initial evaluation.
ANTONY, France, October 27 /PRNewswire-FirstCall/ -- Stallergenes has just obtained authorization (IND(1)) from the FDA for immediately launching a phase III clinical trial in the United States with Oralair(R) Grasses in the treatment of allergic rhinoconjunctivitis to grass pollens in adults.
Regulatory News: Meda AB (STO:MEDAA): The U.S. Food and Drug Administration (FDA) has approved Astepro - the new formulation of Astelin. Astepro Nasal Spray is an improvement over the marketed Astelin Nasal Spray and is better tolerated by patients using the new spray.
Thai researchers suggest patients on allergy medicine are better served when they adjust their dose to symptoms.
Circassia, a specialty biopharmaceutical company, has started a further Phase II clinical study of its ToleroMune technology in the field of cat allergy.
OXFORD, England, October 2 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on the fields of allergy and critical care, today announced the start of a further phase II clinical study of its ToleroMune(R) technology in the field of cat allergy.
Breathe Again(TM), Europe's best selling hypertonic saline nasal spray, is now available in the United States. Clinically tested in France, Breathe Again (www.breatheagain.us) is 100% natural, combining the benefits of pure seawater and the drying effect of a hypertonic solution.
Sanofi-Aventis has announced that the FDA has approved Nasacort AQ nasal spray for children aged two to five years old for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis.
Nasacort, a nasal steroid used in allergic rhinitis, has been approved for the treatment of children aged two to five years old.